-

Hims & Hers Certified as a ‘Great Place to Work’

Results from a new survey of Hims & Hers’ employees has certified the company as a ‘great place to work’ for 2023

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, has been certified as a great place to work this month by the independent analyst Great Place to Work® for the year 2023.

The certification was based on anonymous feedback from Hims & Hers' employees who responded to a survey looking at multiple aspects of the company such as leadership and workplace practices. Results from the survey said that 91% of employees listed Hims & Hers as a great place to work, compared to 57% of employees at “a typical U.S.-based company.”

"We are honored to be certified by Great Place to Work®," said Andrew Dudum, Co-founder and CEO of Hims & Hers. "Our employees are a talented and passionate group of individuals who strive to enhance the lives of our consumers, holding true to our mission to help the world feel great. Every employee at Hims & Hers knows our mission is deeply personal—because we too are customers."

This certification shows that Hims & Hers has demonstrated excellence in the workplace and are committed to providing an inclusive work environment resulting in high levels of employee satisfaction.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

Hims & Hers Health, Inc.

NYSE:HIMS

Release Versions

More News From Hims & Hers Health, Inc.

Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers’ first international generic GLP-1 offering, demonstrating the company’s ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making...

Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada

TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149/month CAD. GLP-1 treatments have transformed obesity and metabolic health, with...

Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced of...
Back to Newsroom